Pfizer and BioNTech have announced a new agreement with the European Commission (EC) to supply 900 million doses of Comirnaty, the companies’ COVID-19 vaccine, to the European Union (EU), with an option for the EC to request up to an additional 900 million doses.
This new agreement is in addition to the 600 million doses that have already been committed to the EU through 2021.
The additional 900 million agreed doses are expected to be delivered on a monthly schedule beginning December 2021 and continuing into 2023.
As part of the agreement, the EC also has an option to increase the number of doses delivered by up to an additional 900 million, bringing the total number of potential doses delivered to the EC, inclusive of all agreements, to up to 2.4 billion.
All doses for the EC are planned to be manufactured in the EU.
“Ongoing vaccination beyond 2021 is critical as COVID-19 continues to spread rapidly throughout Europe and the globe,” said Albert Bourla, Chairman and CEO of Pfizer.
“More than a year later, we continue to learn about COVID-19 and are working to determine if, similar to seasonal influenza, annual vaccination may provide the most enduring protection.”
Ugur Sahin, CEO and Co-Founder of BioNTech, added: “There is growing evidence that COVID-19 will continue to pose a public health challenge for years. This contract with the European Commission will ensure sufficient doses of COMIRNATY are available for all EU citizens in 2022 and 2023.
“With these additional doses and our continued investments in research and development aimed at adapting our vaccine to address new and emerging variants, we will continue to make a significant impact in the EU’s efforts to protect public health.”